P2RY1 and atherosclerosis: Studies have shown that several purinergic receptors, such as A3, P2X4, P2X7, P2Y1, P2Y6, and P2Y12 receptors, contribute to the initiation and progression of atherosclerosis and targeting them has shown therapeutic potential [3, 4].